Asthma
COPD
Pulmonary
Pulmonary: Page 10
Respiratory bacteria disable immune system
Study findings show how a common bacterium survives through illness.
July 19, 2024
Potential cell therapy option for NSCLC
Clinical trial evaluates use of TIL therapy to destroy lung cancer tumor cells.
July 8, 2024
Positive results for investigational drug brensocatib
Insmed presented additional data from its ASPEN study at the World Bronchiectasis Conference.
July 8, 2024
Sponsored
CDC respiratory virus guidance
Ascend Media
Review recommendations and updates to help prevent illness.
April 10, 2025
A microrobotic feat of engineering
Green algae-based microrobots improve lung cancer survival time by almost 40% in mouse models.
July 3, 2024
Using acetaminophen to help treat sepsis patients
NIH researchers evaluate the therapy for critically ill patients at risk of organ damage and respiratory distress.
July 3, 2024
ALA announces online Wellness Hub for lung disease community
The new hub, part of ALA’s Patient & Caregiver Network, will provide physical and mental health benefits for people living with lung disease.
June 26, 2024
Sponsored
CDC respiratory virus guidance
Ascend Media
Review recommendations and updates to help prevent illness.
April 10, 2025
Impact of FOXF1 on rare pediatric lung disease
Study on gene protein may also have implications for common pulmonary conditions.
June 25, 2024
Leveraging AI to predict, diagnose lung cancer
A novel lab-based blood test could move the needle on leading cause of cancer in the U.S.
June 20, 2024
PAH drug trial falls short
Aerovate ends study early upon failing to meet clinical endpoints for its sole product.
June 18, 2024
Sponsored
CDC respiratory virus guidance
Ascend Media
Review recommendations and updates to help prevent illness.
April 10, 2025
RNA-based CF therapy gets the fast track
Biotech company SpliSense moves forward in development of ASO product to treat cystic fibrosis.
June 13, 2024
Lixudebart receives FDA Orphan Drug status
The anti-CLDN1 antibody has been developed to treat IPF.
June 13, 2024
Positive results of new formulation, administration of Rybrevant
Johnson & Johnson demonstrates efficacy in fourth phase 3 clinical trial of the drug therapy.
June 5, 2024
Previous Page
Page 10 of 20
Next Page
Most Popular
CHEST publishes new guideline on NSCLC management
Alternative inflammatory pathways drive residual asthma exacerbations in children treated with mepolizumab
Study points toward potential screening test for COPD
Telehealth, home oxygen therapy could reduce readmissions in COPD patients
Language barriers linked to poorer asthma outcomes
Ethris launches phase 2a clinical trial of mRNA candidate for asthma